Metastatic Urothelial Cancer Completed Phase 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0066157 (Metastatic Urothelial Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03448718Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsTreatment